The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2307-2313

  Martschick, A ^a   Sehouli, J ^a   Patzelt, Alexa ^a   Richter, H ^a   Jacobi, U ^a   Oskay Ozcelik G ^a   Sterry, W ^a   Lademann, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anthracycline; Doxorubicin; Epirubicin; Hand foot syndrome; PPE

Indexed keywords

CETUXIMAB; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; FLUORESCENCE; FOOT SOLE; HAND FOOT SYNDROME; HAND PALM; HUMAN; LASER MICROSCOPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; SKIN PENETRATION; SKIN SURFACE; STRATUM CORNEUM; SWEAT GLAND;

ADULT; AGED; BREAST NEOPLASMS; DOXORUBICIN; DRUG ERUPTIONS; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 67650895857     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G and Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 266: 216-221, 1999. (Pubitemid 29047483)
2. van Asperen J., van TO and Beijnen JH: Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 712: 129-143, 1998. (Pubitemid 28322428)
3. Speth PA, van Hoesel QG and Haanen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15-31, 1988.
4. Charrois GJ and Allen TM: Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306: 1058-1067, 2003. (Pubitemid 37025314)
5. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR and VonRoenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169-2173, 1995.
6. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T and Gabizon A: Skin toxic effects of polyethylene glycolcoated liposomal doxorubicin. Arch Dermatol 136: 1475-1480, 2000. (Pubitemid 32009267)
7. Zuehlke RL: Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 148: 90-92, 1974.
8. Fitzpatrick JE: The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20: 1-14, 1993.
9. Cox GJ and Robertson DB: Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 122: 1413-1414, 1986. (Pubitemid 17191468)
10. DeSpain JD: Dermatologic toxicity of chemotherapy. Semin Oncol 19: 501-507, 1992.
11. Skelton H, Linstrum J and Smith K: Host vs.-altered-host eruptions in patients on liposomal doxorubicin. J Cutan Pathol 29: 148-153, 2002. (Pubitemid 34478260)
12. Susser WS, Whitaker-Worth DL and Grant-Kels JM: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40: 367-398, 1999.
13. Asgari MM, Haggerty JG, McNiff JM, Milstone LM and Schwartz PM: Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 26: 287-294, 1999. (Pubitemid 29373926)
14. Mrozek-Orlowski ME, Frye DK and Sanborn HM: Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 26: 753-762, 1999.
15. Schmook T, Jacobi U, Lademann J, Worm M and Stockfleth E: Detection of doxorubicin in the horny layer in a patient suffering from palmar-plantar erythrodysaesthesia. Dermatology 210: 237-238, 2005.
16. Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W and Lademann J: Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16: 1210-1211, 2005.
17. Drummond DC, Meyer O, Hong K, Kirpotin DB and Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743, 1999.
18. Mahnik SN, Rizovski B, Fuerhacker M and Mader RM: Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere 65: 1419-1425, 2006. (Pubitemid 44427880)
19. Common Toxicity Criteria - V. 1.0 of the National Cancer Institute. www.ucdmc.ucdavis.edu/clinicaltrials/documents/NCI-toxicity-table pdf 2007.
20. Meyer L, Otberg N, Richter H, Sterry W and Lademann J: New prospects in dermatology: Fiber-based confocal scanning laser microscopy. Laser Physics 16: 758-764, 2006. (Pubitemid 44726175)
21. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ and Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993, 1997. (Pubitemid 27106281)
22. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W and Sehouli J: Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer 2007.
23. Harris R, Jones HE and Artis WM: Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 24: 876-882, 1983.
24. Patzelt A, Lademann J and Sterry W: Skin penetration from the inside to the outside: a mini review. Drug Discovery Today, 2008.
25. Hwang K and Baik SH: Distribution of hairs and sweat glands on the bodies of Korean adults: a morphometric study. Acta Anat (Basel) 158: 112-120, 1997. (Pubitemid 27392072)
26. Ya-Xian Z, Suetake T and Tagami H: Number of cell layers of the stratum corneum in normal skin - relationship to the anatomical location on the body, age, sex and physical parameters. Arch Dermatol Res 291: 555-559, 1999.
27. Gerbrecht BM: Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 26: 161-167, 2003. (Pubitemid 36396855)
28. Nagore E, Insa A and Sanmartin O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ("hand-foot") syndrome. Incidence, recognition and management. Am J Clin Dermatol 1: 225-234, 2000.
29. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989. (Pubitemid 19098135)
30. Molpus KL, Anderson LB, Craig CL and Puleo JG: The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93: 513-516, 2004. (Pubitemid 38507627)
31. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM and Alberts DS: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44: 303-306, 1999. (Pubitemid 29402199)
32. Atkins JN: Fluorouracil and the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 102: 419, 1985.
33. Brown J, Burck K, Black D and Collins C: Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 24: 1023-1025, 1991.
34. Hoff PM, Valero V, Ibrahim N, Willey J and Hortobagyi GN: Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82: 965-969, 1998. (Pubitemid 28104178)
35. Hui YF and Cortes JE: Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20: 1221-1223, 2000. (Pubitemid 30768344)